The State of Cancer Care in Russia: Malignant Tumors of the Eye and Adnexa (C69). Prevalence and Year-by-year Mortality. Part 1 (population-based study)

Until 2011, taking into account the rarity of the reported cases of morbidity, malignant tumors of the eye (C69) were not included in the state reports of the Ministry of Health of the Russian Federation. In the state mortality statistics, the C69 isn’t taken into account separately. Currently, it is possible to get a real idea of the prevalence and effectiveness of anti-cancer measures in relation to the C69 heading only using Population-based Cancer Registries (PCR) created in the country.

The purpose of our study is to continue studying the features of the dynamics of morbidity, year-by-year mortality and survival of patients with cancer of the eye and adnexa in Russia on the basis of state reporting forms and the database (DB) of the PCR.

Methods. Standard methods of oncological statistics were used in accordance with international requirements.

Results. In Russia, more than 1 thousand (1184 — 2023) new cases of malignant tumors of the eye (C69) are detected annually. The gross incidence rate increased in Russia from 0.65 (2011) to 0.810/0000 (2023) or by 24.62 %, the standardized, eliminating differences in the age composition of the population increased by only 5.6 %, amounting to 0.56 0/0000 by 2023. From 2019 to 2020 established the negative impact of coronavirus infection, its effect on patients turned out to be almost the same in Russia as for all malignant tumors (-14.3 %). The oneand five-year observed and relative survival rates continued to increase.

Conclusion. The conducted study confirmed the previously identified patterns of the dynamics of the prevalence of malignant tumors of the eye and adnexa. The PCR of the Northwestern Federal District of the Russian Federation remains the only territory of Russia that carries out an in-depth analysis of the state of the oncological service using the PCR database at the federal district level.

1. Merabishvili VM, Merabishvili EN. Dynamics of observed and relative survival of patients with malignant tumors of the eye and adnexa. Ophthalmology in Russia. 2012;9(2):49–53 (In Russ.). doi: 10.18008/1816-5095-2012-2-49-53.

2. Merabishvili VM, Merabishvili EN. Malignant tumors of the eye and adnexa, morbidity and mortality (population-based study). Ophthalmology in Russia. 2012;9(3):71–76 (In Russ.). doi: 10.18008/1816-5095-2012-3-71-76.

3. Merabishvili VM, Merabishvili EN. Epidemiology malignant tumors of the eye and its adnexa (population based study). Ophthalmology in Russia. 2015;12(4):64–74 (In Russ.). doi: 10.18008/1816-5095-2015-4-64-74.

4. Merabishvili VM, Merabishvili EN. Age-related features of the prevalence and survival of patients with malignant tumors of the eye and its adnexa (c69) with taking into account the localization and histological structure: population study. Advances of Gerantology. 2020;.33(3):561–568 (In Russ.). doi: 10.34922/AE.2020.33.3.019.

5. Merabishvili VM, Merabishvili EN. The Prevalence of Malignant Tumors of the Eye and Adnexa (C69). Ophthalmology in Russia. 2020;17(3):495–501 (In Russ.). doi: 10.18008/1816-5095-2020-3-495-501.

6. Merabishvili VM, Merabishvili EN. Structure of Oncological Pathology and Survival of Patients with Malignant Tumors of the Eye and Adnexa (C69) Taking into Account Sex, Age and Histological Characteristics (Population Study). Ophthalmology in Russia. 2021;18(3):578–583 (In Russ.). doi: 10.18008/1816-5095-2021-3-578-583.

7. Cancer Incidence in Five Continents. Volume XII. Registry Summary tables. URL: https://ci5.iarc.fr/ci5-xii/tables/summary (accessed 2.12.2024).

8. Malignant tumors in Russia in 2011 (morbidity and mortality) / Ed. V.I. Chissova, V.V. Starinskogo, G.V. Petrovoi. Moscow: P.A. Herzen MSIOI, 2013:289 (In Russ.).

9. Malignant tumors in Russia in 2015 (morbidity and mortality). Ed. A.D. Kaprin, V.V. Starinskogo, G.V. Petrovoi. — Moscow: P.A. Herzen MSIOI — filial of NMRC of radiology, 2016:250 (In Russ.).

10. Malignant tumors in Russia in 2019 (morbidity and mortality). Ed. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoi. Moscow: P.A. Herzen MSIOI — filial of NMRC of radiology, 2020:214 (In Russ.).

11. Malignant tumors in Russia in 2020 (morbidity and mortality). Ed. A.D. Kaprina, V.V. Starinskogo, A.O. Shahzadovoi. Moscow: P.A. Herzen MSIOI — filial of NMRC of radiology, 2021:252 (In Russ.).

12. Malignant tumors in Russia in 2020 (morbidity and mortality). Ed. A.D. Kaprina, V.V. Starinskogo, A.O. Shahzadovoi. Moscow: P.A. Herzen MSIOI — filial of NMRC of radiology, 2022:252 (In Russ.).

13. Malignant tumors in Russia in 2022 (morbidity and mortality). Ed. A.D. Kaprina, V.V. Starinskogo, A.O. Shakhzadova, I.V. Lisichnikovoi. Moscow: P.A. Herzen MSIOI — filial of NMRC of radiology, 2023:275 (In Russ.).

14. Malignant tumors in Russia in 2023 (morbidity and mortality). Ed. A.D. Kaprina, et al. Moscow: P.A. Herzen MSIOI — filial of NMRC of radiology, 2024:276 (In Russ.).

15. Merabishvili VM. Covid and cancer in Russia. Questions of oncology. 2022;68(4):381–392. (In Russ.). doi: 10.37469/0507-3758-2022-68-4-381-392.